A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Recruiting

Phase 3

Cabotegravir & RilpivirineA Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Sponsor:

ViiV Healthcare

Code:

NCT06694805

Conditions

HIV Infections

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

CAB LA + RPV LA

Oral ART

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-23. This information was provided to ClinicalTrials.gov by ViiV Healthcare on 2025-09-03.